跳转至内容
Merck
CN

Inactivating PAPSS2 mutations in a patient with premature pubarche.

The New England journal of medicine (2009-05-29)
Cees Noordam, Vivek Dhir, Joanne C McNelis, Florian Schlereth, Neil A Hanley, Nils Krone, Jan A Smeitink, Roel Smeets, Fred C G J Sweep, Hedi L Claahsen-van der Grinten, Wiebke Arlt
摘要

Dehydroepiandrosterone (DHEA) sulfotransferase, known as SULT2A1, converts the androgen precursor DHEA to its inactive sulfate ester, DHEAS [corrected], thereby preventing the conversion of DHEA to an active androgen. SULT2A1 requires 3'-phosphoadenosine-5'-phosphosulfate (PAPS) for catalytic activity. We have identified compound heterozygous mutations in the gene encoding human PAPS synthase 2 (PAPSS2) in a girl with premature pubarche, hyperandrogenic anovulation, very low DHEAS levels, and increased androgen levels. In vitro coincubation of human SULT2A1 and wild-type or mutant PAPSS2 proteins confirmed the inactivating nature of the mutations. These observations indicate that PAPSS2 deficiency is a monogenic adrenocortical cause of androgen excess.